CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma
University of California, Davis
University of California, Davis
Celgene
National Institutes of Health Clinical Center (CC)
Celgene
Celgene